RAPS Practice Exam 2025 (Devices)
Terms in this set (50)
Prior to initiating a clinical Re-evaluate the nonclinical data before proceeding with the clinical
trail, the company discovers trial
that the non-clinical study
Explanation:
results were incorrectly
Ensuring the accuracy of nonclinical data is crucial before
documented. Which of the
starting a clinical trial. Re- evaluating the data will help
following is the MOST
confirm that the foundation for the clinical study is
appropriate course of action
reliable and meets regulatory requirements.
for the company?
Notify the IRB ethics
committee and obtain a re-
approval for the trial
Proceed with the clinical
trial, but initiate protocol
amendments to address the
errors Re-evaluate the
nonclinical data before
proceeding with the clinical
trial
Revalidate the protocol and
repeat the nonclinical studies
if necessary
,Your company is planning to d. A and C
market a Class II stand-
alone medical device Explanation:
software in the US. The a. The UDI should be conveyed in an easily readable
software will not be format within the software interface or on the website. This
distributed in packaged form ensures the UDI is available in the context where the
and will instead be provided software is accessed or used.
for download from the c. The UDI should be conveyed in an easily readable format
company website. As a within the software itself. This ensures that users can find
regulatory lead, you are and verify the UDI once the software is downloaded and in
asked to provide guidance use.
on Unique Device Identifier Both a and c ensure that the UDI is presented in a format
(UDI) compliance for this that is accessible and readable both at the point of
advice. You advise the download and within the software.
development team that the
Product Identifier (PI) will
need to include the software
version number. When asked
how the UDI must be
presented, how do you
advise the team?
a. The UDI should be
conveyed in an easily
readable format within the
software interface or on the
website.
b. The UDI should be conveyed
in an easily readable format
that can be accessed
through the website.
c. The UDI should be conveyed
in an easily readable format
within the software itself.
d. A and C
What source should the b) The Orange Book
regulatory professional
consult to determine when a Explanation:
product's patent and The Orange Book (Approved Drug Products with
exclusivity will expire? Therapeutic Equivalence Evaluations) lists patents and
exclusivity information for FDA-approved drug products. It
a) Federal
Register provides details on patent expiration dates and periods of
b)The Orange Book exclusivity.
, c) Patentand Trademark Office
d) Copyright Office
You are tasked with helping d) All options listed above should be considered
develop a regulatory
intelligence procedure for Explanation:
continuously collecting and For a comprehensive regulatory intelligence procedure, it's
analyzing regulatory important to consider a variety of inputs including sources
information pertaining to of content, government publications, and databases of
chromosome enumeration standards and guidelines to ensure thorough and up-to-
probes (CEPs), a type of in date regulatory analysis.
vitro diagnostic (IVD) device.
Which of the following
inputs should be considered
when creating this procedure?
a) Sources of content (for
example - blogs and white
papers)
b) Identification of applicable
government publications
and regulations
c) Databases containing
international standards
and guidelines
d) All options listed above
should be considered
Terms in this set (50)
Prior to initiating a clinical Re-evaluate the nonclinical data before proceeding with the clinical
trail, the company discovers trial
that the non-clinical study
Explanation:
results were incorrectly
Ensuring the accuracy of nonclinical data is crucial before
documented. Which of the
starting a clinical trial. Re- evaluating the data will help
following is the MOST
confirm that the foundation for the clinical study is
appropriate course of action
reliable and meets regulatory requirements.
for the company?
Notify the IRB ethics
committee and obtain a re-
approval for the trial
Proceed with the clinical
trial, but initiate protocol
amendments to address the
errors Re-evaluate the
nonclinical data before
proceeding with the clinical
trial
Revalidate the protocol and
repeat the nonclinical studies
if necessary
,Your company is planning to d. A and C
market a Class II stand-
alone medical device Explanation:
software in the US. The a. The UDI should be conveyed in an easily readable
software will not be format within the software interface or on the website. This
distributed in packaged form ensures the UDI is available in the context where the
and will instead be provided software is accessed or used.
for download from the c. The UDI should be conveyed in an easily readable format
company website. As a within the software itself. This ensures that users can find
regulatory lead, you are and verify the UDI once the software is downloaded and in
asked to provide guidance use.
on Unique Device Identifier Both a and c ensure that the UDI is presented in a format
(UDI) compliance for this that is accessible and readable both at the point of
advice. You advise the download and within the software.
development team that the
Product Identifier (PI) will
need to include the software
version number. When asked
how the UDI must be
presented, how do you
advise the team?
a. The UDI should be
conveyed in an easily
readable format within the
software interface or on the
website.
b. The UDI should be conveyed
in an easily readable format
that can be accessed
through the website.
c. The UDI should be conveyed
in an easily readable format
within the software itself.
d. A and C
What source should the b) The Orange Book
regulatory professional
consult to determine when a Explanation:
product's patent and The Orange Book (Approved Drug Products with
exclusivity will expire? Therapeutic Equivalence Evaluations) lists patents and
exclusivity information for FDA-approved drug products. It
a) Federal
Register provides details on patent expiration dates and periods of
b)The Orange Book exclusivity.
, c) Patentand Trademark Office
d) Copyright Office
You are tasked with helping d) All options listed above should be considered
develop a regulatory
intelligence procedure for Explanation:
continuously collecting and For a comprehensive regulatory intelligence procedure, it's
analyzing regulatory important to consider a variety of inputs including sources
information pertaining to of content, government publications, and databases of
chromosome enumeration standards and guidelines to ensure thorough and up-to-
probes (CEPs), a type of in date regulatory analysis.
vitro diagnostic (IVD) device.
Which of the following
inputs should be considered
when creating this procedure?
a) Sources of content (for
example - blogs and white
papers)
b) Identification of applicable
government publications
and regulations
c) Databases containing
international standards
and guidelines
d) All options listed above
should be considered
